Structure-Function Studies of Polymyxin B Lipononapeptides.


Journal

Molecules (Basel, Switzerland)
ISSN: 1420-3049
Titre abrégé: Molecules
Pays: Switzerland
ID NLM: 100964009

Informations de publication

Date de publication:
02 Feb 2019
Historique:
received: 21 12 2018
revised: 26 01 2019
accepted: 27 01 2019
entrez: 6 2 2019
pubmed: 6 2 2019
medline: 4 6 2019
Statut: epublish

Résumé

The emerging threat of infections caused by highly drug-resistant bacteria has prompted a resurgence in the use of the lipodecapeptide antibiotics polymyxin B and colistin as last resort therapies. Given the emergence of resistance to these drugs, there has also been a renewed interest in the development of next generation polymyxins with improved therapeutic indices and spectra of action. We report structure-activity studies of 36 polymyxin lipononapeptides structurally characterised by an exocyclic FA-Thr²-Dab³ lipodipeptide motif instead of the native FA-Dab¹-Thr²-Dab³ tripeptide motif found in polymyxin B, removing one of the positively charged residues believed to contribute to nephrotoxicity. The compounds were prepared by solid phase synthesis using an on-resin cyclisation approach, varying the fatty acid and the residues at position 2 (P2), P3 and P4, then assessing antimicrobial potency against a panel of Gram-negative bacteria, including polymyxin-resistant strains. Pairwise comparison of

Identifiants

pubmed: 30717415
pii: molecules24030553
doi: 10.3390/molecules24030553
pmc: PMC6384738
pii:
doi:

Substances chimiques

Anti-Infective Agents 0
Fatty Acids 0
Peptides 0
Polymyxin B J2VZ07J96K

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Health and Medical Research Council
ID : APP1005350, APP1045326 and APP1139609
Organisme : National Institutes of Health
ID : R21AI098731/R33AI098731
Organisme : Wellcome Trust
ID : Seeding Drug Discovery Award (094977/Z/10/Z) and Wellcome Trust Strategic Grant (104797/Z/14/Z).
Pays : United Kingdom
Organisme : National Health and Medical Research Council
ID : APP1059354

Références

Antimicrob Agents Chemother. 1999 Jun;43(6):1317-23
pubmed: 10348745
J Med Chem. 2000 Aug 10;43(16):3085-92
pubmed: 10956216
J Bacteriol. 1947 Nov;54(5):549-56
pubmed: 16561391
Nature. 1949 Apr 16;163(4146):611
pubmed: 18117140
Antimicrob Agents Chemother. 2008 Sep;52(9):3229-36
pubmed: 18591267
J Antibiot (Tokyo). 1977 May;30(5):427-9
pubmed: 195923
J Med Chem. 2010 Mar 11;53(5):1898-916
pubmed: 19874036
J Antibiot (Tokyo). 1977 Sep;30(9):767-9
pubmed: 200598
J Antibiot (Tokyo). 1977 Dec;30(12):1029-34
pubmed: 202582
Bull Johns Hopkins Hosp. 1947 Jul;81(1):43-54
pubmed: 20259524
J Bacteriol. 1947 Jul;54(1):24
pubmed: 20344246
Chem Pharm Bull (Tokyo). 2011;59(5):597-602
pubmed: 21532197
Microb Drug Resist. 2012 Apr;18(2):132-6
pubmed: 22196342
Ann N Y Acad Sci. 2013 Jan;1277:84-90
pubmed: 23346859
J Med Chem. 2013 Jun 27;56(12):5079-93
pubmed: 23735048
ACS Chem Biol. 2014 May 16;9(5):1172-7
pubmed: 24601489
Expert Opin Drug Metab Toxicol. 2014 Dec;10(12):1621-35
pubmed: 25382677
Lancet Infect Dis. 2015 Feb;15(2):225-34
pubmed: 25459221
Sci Rep. 2015 May 29;5:10558
pubmed: 26024044
Pharmacol Res Perspect. 2015 Jun;3(3):e00148
pubmed: 26171227
J Med Chem. 2016 Feb 11;59(3):1068-77
pubmed: 26734854
J Antibiot (Tokyo). 2017 Jan;70(1):3-24
pubmed: 27353164
Int J Antimicrob Agents. 2016 Dec;48(6):583-591
pubmed: 27524102
ACS Infect Dis. 2015 Nov 13;1(11):568-575
pubmed: 27525307
Int J Antimicrob Agents. 2016 Dec;48(6):592-597
pubmed: 27793510
Pharmacotherapy. 2017 Jan;37(1):71-84
pubmed: 27859453
Antimicrob Agents Chemother. 2017 Feb 23;61(3):
pubmed: 27993859
Antimicrob Agents Chemother. 2017 Mar 24;61(4):
pubmed: 28096166
Peptides. 2017 May;91:8-12
pubmed: 28300674
Bioorg Med Chem Lett. 2017 Jun 1;27(11):2407-2409
pubmed: 28454673
Antimicrob Agents Chemother. 2017 Jul 25;61(8):
pubmed: 28533232
Nat Prod Rep. 2017 Jul 6;34(7):886-908
pubmed: 28628170
Antimicrob Agents Chemother. 2017 Dec 21;62(1):
pubmed: 29038269
Med Sci (Basel). 2017 Dec 21;6(1):null
pubmed: 29267233
Antimicrob Agents Chemother. 2018 Sep 24;62(10):
pubmed: 30061284
Antimicrob Agents Chemother. 1986 Aug;30(2):340-1
pubmed: 3021053
Nature. 1966 Oct 15;212(5059):311
pubmed: 4291533

Auteurs

Alejandra Gallardo-Godoy (A)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. a.gallardogodoy@uq.edu.au.

Karl A Hansford (KA)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. k.hansford@uq.edu.au.

Craig Muldoon (C)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. cmouldy@yahoo.com.au.

Bernd Becker (B)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. bbeckerr@gmail.com.

Alysha G Elliott (AG)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. a.elliott@imb.uq.edu.au.

Johnny X Huang (JX)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. johnny.xiao.huang@gmail.com.

Ruby Pelingon (R)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. r.pelingon@imb.uq.edu.au.

Mark S Butler (MS)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. m.butler5@uq.edu.au.

Mark A T Blaskovich (MAT)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. m.blaskovich@uq.edu.au.

Matthew A Cooper (MA)

Institute for Molecular Bioscience, The University of Queensland, Brisbane, Queensland 4072, Australia. m.cooper@uq.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH